Eiki Ichihara

7.4k citations
160 papers · 2.5k · h-index 29

Impact in

  • Oncology top 2%
    • Lung Cancer Research Studies
    • Cancer Immunotherapy and Biomarkers
    • HER2/EGFR in Cancer Research
    • Colorectal Cancer Treatments and Studies
  • Pulmonary and Respiratory Medicine top 1%
    • Lung Cancer Treatments and Mutations

Papers in

  • Pulmonary and Respiratory Medicine 102
    • Lung Cancer Treatments and Mutations 85
    • Lung Cancer Diagnosis and Treatment 15
  • Oncology 83
    • Cancer Immunotherapy and Biomarkers 27
    • Lung Cancer Research Studies 21
    • Colorectal Cancer Treatments and Studies 20
    • HER2/EGFR in Cancer Research 12
Co-authors
Katsuyuki Kiura (123 shared papers)Nagio Takigawa (58 shared papers)Mitsune Tanimoto (56 shared papers)Katsuyuki Hotta (94 shared papers)Nobuaki Ochi (30 shared papers)Toshio Kubo (55 shared papers)Kadoaki Ohashi (62 shared papers)Masahiro Tabata (56 shared papers)
Journals
Cancer Research (17 papers)Japanese Journal of Clinical Oncology (13 papers)Journal of Clinical Oncology (11 papers)Lung Cancer (9 papers)Annals of Oncology (7 papers)
Partner nations
JapanUnited StatesUnited Kingdom

In The Last Decade

Eiki Ichihara

141 papers receiving 2.5k citations

Peers

Eiki Ichihara
Comparison fields: 5 of 81
  • Oncology 1.2k
  • Pulmonary and Respiratory Medicine 1.2k
  • Cancer Research 308
  • Molecular Biology 803
  • Pathology and Forensic Medicine 166
Replace Roberta Minari with:
Roberta Minari Italy
Alessandro Leonetti Italy
Kenji Tomizawa Japan
Shang‐Gin Wu Taiwan
Kazuhiko Shien Japan
Takehito Shukuya Japan
Matthew J. Niederst United States
G. Deplanque France
Chiara Lazzari Italy
Giulia Pasello Italy
Eiki Ichihara relative to Roberta Minari Italy Roberta Minari's profile →
Citations per field
00.5×5×10×17.3×
Roberta Minari · 1×
Citations per year

Countries citing papers authored by Eiki Ichihara

Since Specialization
Citations

This map shows the geographic impact of Eiki Ichihara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eiki Ichihara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eiki Ichihara more than expected).

Fields of papers citing papers by Eiki Ichihara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eiki Ichihara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eiki Ichihara. The network helps show where Eiki Ichihara may publish in the future.

Co-authors

The 25 scholars most cited alongside Eiki Ichihara, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eiki Ichihara Line = papers co-authored together Eiki Ichihara links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 160 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell–like Properties in Cancer Cells
Cancer Research ·Kazuhiko Shien, Shinichi Toyooka, Hiromasa Yamamoto, Junichi Soh, Masaru Jida, Kelsie L. Thu, Shinsuke Hashida, Yuho Maki, Eiki Ichihara, Hiroaki Asano, Kazunori Tsukuda, Nagio Takigawa, Katsuyuki Kiura, Adi F. Gazdar, Wan L. Lam, Shinichiro Miyoshi
2013227
2
A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer
Journal of Thoracic Oncology ·Katsuyuki Hotta, Keisuke Aoe, Toshiyuki Kozuki, Kadoaki Ohashi, Kiichiro Ninomiya, Eiki Ichihara, Toshio Kubo, Takashi Ninomiya, Kenichi Chikamori, Daijiro Harada, Naoyuki Nogami, Taizo Hirata, Shiro Hinotsu, Shinichi Toyooka, Katsuyuki Kiura
2017128
3
Liposomal Delivery of MicroRNA-7–Expressing Plasmid Overcomes Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistance in Lung Cancer Cells
Molecular Cancer Therapeutics ·Kammei Rai, Nagio Takigawa, Sachio Ito, Hiromi Kashihara, Eiki Ichihara, Tatsuji Yasuda, Kenji Shimizu, Mitsune Tanimoto, Katsuyuki Kiura
2011110
4
Non–Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases
Cancer Research ·Hideko Isozaki, Eiki Ichihara, Nagio Takigawa, Kadoaki Ohashi, Nobuaki Ochi, Masayuki Yasugi, Takashi Ninomiya, Hiromichi Yamane, Katsuyuki Hotta, Katsuya Sakai, Kunio Matsumoto, Shinobu Hosokawa, Akihiro Bessho, Toshiaki Sendo, Mitsune Tanimoto, Katsuyuki Kiura
2016108
5
SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer
Cancer Research ·Eiki Ichihara, David Westover, Catherine B. Meador, Yingjun Yan, Joshua A. Bauer, Lu Wang, Fei Ye, Amanda Kulick, Elisa de Stanchina, Robert McEwen, Marc Ladanyi, Darren A.E. Cross, William Pao, Christine M. Lovly
2017106
6
Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001
Journal of Thoracic Oncology ·Eiki Ichihara, Katsuyuki Hotta, Naoyuki Nogami, Shoichi Kuyama, Daizo Kishino, Masanori Fujii, Toshiyuki Kozuki, Masahiro Tabata, Daijiro Harada, Kenichi Chikamori, Keisuke Aoe, Hiroshi Ueoka, Shinobu Hosokawa, Akihiro Bessho, Akiko Hisamoto-Sato, Toshio Kubo, Isao Oze, Nagio Takigawa, Mitsune Tanimoto, Katsuyuki Kiura
201587
7
The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer
Lung Cancer ·Eiki Ichihara, Daijiro Harada, Koji Inoue, Ken Sato, Shinobu Hosokawa, Daizo Kishino, Kazuhiko Watanabe, Nobuaki Ochi, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura
201974
8
Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systemic Review
PLoS ONE ·Katsuyuki Hotta, Katsuyuki Kiura, Yoshiro Fujiwara, Nagio Takigawa, Akiko Hisamoto, Eiki Ichihara, Masahiro Tabata, Mitsune Tanimoto
201163
9
The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer
Japanese Journal of Clinical Oncology ·Hiromi Watanabe, Toshio Kubo, Kiichiro Ninomiya, Kenichiro Kudo, Daisuke Minami, Etsuko Murakami, Nobuaki Ochi, Takashi Ninomiya, Daijiro Harada, Masayuki Yasugi, Eiki Ichihara, Kadoaki Ohashi, Keiichi Fujiwara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura
201961
10
Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation In vivo
Cancer Research ·Eiki Ichihara, Kadoaki Ohashi, Nagio Takigawa, Masahiro Osawa, Atsuko Ogino, Mitsune Tanimoto, Katsuyuki Kiura
200955
11
Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model
Molecular Cancer Therapeutics ·Takashi Ninomiya, Nagio Takigawa, Eiki Ichihara, Nobuaki Ochi, Toshi Murakami, Yoshihiro Honda, Toshio Kubo, Daisuke Minami, Kenichiro Kudo, Mitsune Tanimoto, Katsuyuki Kiura
201354
12
Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR -mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.
Journal of Clinical Oncology ·James Chih‐Hsin Yang, Dae Ho Lee, Jong Seok Lee, Yun Fan, Filippo de Marinis, Isamu Okamoto, Takako Inoue, Jerónimo Rafael Rodríguez Cid, Zhang Li, Cheng‐Ta Yang, Emmanuel de la Mora Jimenez, Jianying Zhou, M. Pérol, Ki Hyeong Lee, David Vicente, Eiki Ichihara, Gregory J. Riely, Yiwen Luo, Niyati Bhagwati, Shun Lü
202353
13
Subpopulation of small‐cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy
Cancer Science ·Toshio Kubo, Nagio Takigawa, Masahiro Osawa, Daijiro Harada, Takashi Ninomiya, Nobuaki Ochi, Eiki Ichihara, Hiromichi Yamane, Mitsune Tanimoto, Katsuyuki Kiura
201253
14
Synergistic Effect of Olaparib with Combination of Cisplatin on PTEN -Deficient Lung Cancer Cells
Molecular Cancer Research ·Daisuke Minami, Nagio Takigawa, Hiromasa Takeda, Minoru Takata, Nobuaki Ochi, Eiki Ichihara, Akiko Hisamoto, Katsuyuki Hotta, Mitsune Tanimoto, Katsuyuki Kiura
201251
15
The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non–small-cell lung cancer differ based on PD-L1 expression
European Journal of Cancer ·Nobuaki Ochi, Eiki Ichihara, Nagio Takigawa, Daijiro Harada, Koji Inoue, Takuo Shibayama, Shinobu Hosokawa, Daizo Kishino, Shingo Harita, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura
202146
16
Reappraisal of Short-term Low-volume Hydration in Cisplatin-based Chemotherapy: Results of a Prospective Feasibility Study in Advanced Lung Cancer in the Okayama Lung Cancer Study Group Trial 1002
Japanese Journal of Clinical Oncology ·Katsuyuki Hotta, Nagio Takigawa, Akiko Hisamoto-Sato, Eiki Ichihara, Kenichiro Kudo, Kôji Uchida, Kayo Yanase-Nakamura, Hisaaki Tanaka, Yuka Kato, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura
201344
17
Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer
Experimental Cell Research ·Nobuaki Ochi, Nagio Takigawa, Daijiro Harada, Masayuki Yasugi, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura
201444
18
Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study
Cancer Science ·Hidehito Horinouchi, Naoyuki Nogami, Hideo Saka, Makoto Nishio, Takaaki Tokito, Toshiaki Takahashi, Kazuo Kasahara, Yoshihiro Hattori, Eiki Ichihara, Noriaki Adachi, Kazuo Noguchi, Fabricio Souza, Takayasu Kurata
202140
19
Establishment of pemetrexed-resistant non-small cell lung cancer cell lines
Cancer Letters ·Dan Zhang, Nobuaki Ochi, Nagio Takigawa, Yasushi Tanimoto, Yanyan Chen, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura
201140
20
JAK2‐related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor‐activating mutation
Cancer Science ·Daijiro Harada, Nagio Takigawa, Nobuaki Ochi, Takashi Ninomiya, Masayuki Yasugi, Toshio Kubo, Hiromasa Takeda, Eiki Ichihara, Kadoaki Ohashi, Saburo Takata, Mitsune Tanimoto, Katsuyuki Kiura
201239

About Eiki Ichihara

Eiki Ichihara is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Surgery and Cancer Research, having authored 160 papers that have together received 2.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (85 papers), Cancer Immunotherapy and Biomarkers (27 papers), Lung Cancer Research Studies (21 papers), Colorectal Cancer Treatments and Studies (20 papers), Lung Cancer Diagnosis and Treatment (15 papers), PI3K/AKT/mTOR signaling in cancer (13 papers), HER2/EGFR in Cancer Research (12 papers) and Cancer Mechanisms and Therapy (7 papers). The work is most often cited by research in Oncology (1.2k citations), Pulmonary and Respiratory Medicine (1.2k citations), Cancer Research (308 citations), Molecular Biology (803 citations) and Pathology and Forensic Medicine (166 citations). Eiki Ichihara has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Katsuyuki Kiura, Nagio Takigawa, Mitsune Tanimoto, Katsuyuki Hotta, Nobuaki Ochi, Toshio Kubo, Kadoaki Ohashi, Masahiro Tabata, Takashi Ninomiya and Daijiro Harada. Their work appears in journals such as Cancer Research, Japanese Journal of Clinical Oncology, Journal of Clinical Oncology, Lung Cancer and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roberta MinariBreakdown of academic impact, for papers by Alessandro LeonettiBreakdown of academic impact, for papers by Kenji TomizawaBreakdown of academic impact, for papers by Shang‐Gin WuBreakdown of academic impact, for papers by Kazuhiko ShienBreakdown of academic impact, for papers by Takehito ShukuyaBreakdown of academic impact, for papers by Matthew J. NiederstBreakdown of academic impact, for papers by G. DeplanqueBreakdown of academic impact, for papers by Chiara LazzariBreakdown of academic impact, for papers by Giulia Pasello